Literature DB >> 29848235

American Thyroid Association Statement on Postoperative Hypoparathyroidism: Diagnosis, Prevention, and Management in Adults.

Lisa A Orloff1, Sam M Wiseman2, Victor J Bernet3, Thomas J Fahey4, Ashok R Shaha5, Maisie L Shindo6, Samuel K Snyder7, Brendan C Stack8, John B Sunwoo1, Marilene B Wang9.   

Abstract

BACKGROUND: Hypoparathyroidism (hypoPT) is the most common complication following bilateral thyroid operations. Thyroid surgeons must employ strategies for minimizing and preventing post-thyroidectomy hypoPT. The objective of this American Thyroid Association Surgical Affairs Committee Statement is to provide an overview of its diagnosis, prevention, and treatment.
SUMMARY: HypoPT occurs when a low intact parathyroid hormone (PTH) level is accompanied by hypocalcemia. Risk factors for post-thyroidectomy hypoPT include bilateral thyroid operations, autoimmune thyroid disease, central neck dissection, substernal goiter, surgeon inexperience, and malabsorptive conditions. Medical and surgical strategies to minimize perioperative hypoPT include optimizing vitamin D levels, preserving parathyroid blood supply, and autotransplanting ischemic parathyroid glands. Measurement of intraoperative or early postoperative intact PTH levels following thyroidectomy can help guide patient management. In general, a postoperative PTH level <15 pg/mL indicates increased risk for acute hypoPT. Effective management of mild to moderate potential or actual postoperative hypoPT can be achieved by administering either empiric/prophylactic oral calcium and vitamin D, selective oral calcium, and vitamin D based on rapid postoperative PTH level(s), or serial serum calcium levels as a guide. Monitoring for rebound hypercalcemia is necessary to avoid metabolic and renal complications. For more severe hypocalcemia, inpatient management may be necessary. Permanent hypoPT has long-term consequences for both objective and subjective well-being, and should be prevented whenever possible.

Entities:  

Keywords:  central neck; hypocalcemia; hypoparathyroidism; parathyroid hormone; paresthesia; thyroidectomy

Mesh:

Year:  2018        PMID: 29848235     DOI: 10.1089/thy.2017.0309

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  62 in total

Review 1.  2019 European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioiodine-Refractory Thyroid Cancer.

Authors:  Laura Fugazzola; Rossella Elisei; Dagmar Fuhrer; Barbara Jarzab; Sophie Leboulleux; Kate Newbold; Jan Smit
Journal:  Eur Thyroid J       Date:  2019-08-28

Review 2.  Hypoparathyroidism.

Authors:  John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2020-06-01       Impact factor: 5.958

3.  Central compartment revision surgery for persistent or recurrent thyroid carcinoma: analysis of survival and complication rate.

Authors:  Gabriele Molteni; Marco Bonali; Francesco Mattioli; Michael Ghirelli; Matteo Fermi; Gaetano Ferri; Malagoli Andrea; Livio Presutti
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-12-10       Impact factor: 2.503

Review 4.  Diagnosis and management of hypocalcemia.

Authors:  Jessica Pepe; Luciano Colangelo; Federica Biamonte; Chiara Sonato; Vittoria Carmela Danese; Veronica Cecchetti; Marco Occhiuto; Valentina Piazzolla; Viviana De Martino; Federica Ferrone; Salvatore Minisola; Cristiana Cipriani
Journal:  Endocrine       Date:  2020-05-04       Impact factor: 3.633

Review 5.  Morbidity following thyroid surgery: acceptable rates and how to manage complicated patients.

Authors:  M N Minuto; S Reina; E Monti; G L Ansaldo; E Varaldo
Journal:  J Endocrinol Invest       Date:  2019-05-23       Impact factor: 4.256

6.  Remote-Access Thyroidectomy: A Multi-Institutional North American Experience with Transaxillary, Robotic Facelift, and Transoral Endoscopic Vestibular Approaches.

Authors:  Jonathon O Russell; Christopher R Razavi; Meghan E Garstka; Lena W Chen; Elya Vasiliou; Sang-Wook Kang; Ralph P Tufano; Emad Kandil
Journal:  J Am Coll Surg       Date:  2018-12-23       Impact factor: 6.113

7.  Prevalence and risk factors for hypoparathyroidism following total thyroidectomy in Spain: a multicentric and nation-wide retrospective analysis.

Authors:  Juan J Díez; Emma Anda; Julia Sastre; Begoña Pérez Corral; Cristina Álvarez-Escolá; Laura Manjón; Miguel Paja; Marcel Sambo; Piedad Santiago Fernández; Concepción Blanco Carrera; Juan C Galofré; Elena Navarro; Carles Zafón; Eva Sanz; Amelia Oleaga; Orosia Bandrés; Sergio Donnay; Ana Megía; María Picallo; Cecilia Sánchez Ragnarsson; Gloria Baena-Nieto; José Carlos Fernández García; Beatriz Lecumberri; Manel Sahún de la Vega; Ana R Romero-Lluch; Pedro Iglesias
Journal:  Endocrine       Date:  2019-07-17       Impact factor: 3.633

8.  Hypoparathyroidism After Total Thyroidectomy: Importance of the Intraoperative Management of the Parathyroid Glands.

Authors:  Guillermo Ponce de León-Ballesteros; David Velázquez-Fernández; F Javier Hernández-Calderón; Carlos Bonilla-Ramírez; Rafael H Pérez-Soto; Juan Pablo Pantoja; Mauricio Sierra; Miguel F Herrera
Journal:  World J Surg       Date:  2019-07       Impact factor: 3.352

9.  Permanent postoperative hypoparathyroidism: an analysis of prevalence and predictive factors for adequacy of control in a cohort of 260 patients.

Authors:  Juan J Díez; Emma Anda; Julia Sastre; Begoña Pérez Corral; Cristina Álvarez-Escolá; Laura Manjón; Miguel Paja; Marcel Sambo; Piedad Santiago Fernández; Concepción Blanco Carrera; Juan C Galofré; Elena Navarro; Carles Zafón; Eva Sanz; Amelia Oleaga; Orosia Bandrés; Sergio Donnay; Ana Megía; María Picallo; Cecilia Sánchez Ragnarsson; Gloria Baena-Nieto; José Carlos Fernández-García; Beatriz Lecumberri; Manel Sahún de la Vega; Ana R Romero-Lluch; Pedro Iglesias
Journal:  Gland Surg       Date:  2020-10

Review 10.  Skeletal health in patients with differentiated thyroid carcinoma.

Authors:  M Cellini; M Rotondi; M L Tanda; E Piantanida; L Chiovato; P Beck-Peccoz; Andrea Lania; G Mazziotti
Journal:  J Endocrinol Invest       Date:  2020-07-21       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.